METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo pill could shrink fatty liver and shed pounds
Disease control Recruiting nowThis study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Gene-Silencing drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis Phase 2 trial tests a drug called ALN-HSD, which uses gene silencing to target liver scarring in people with MASH, a fatty liver disease that can lead to cirrhosis. The study enrolls 120 adults with genetic risk factors and moderate-to-severe liver fibrosis. Researchers will…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug aims to shrink fatty liver in early trial
Disease control Recruiting nowThis early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug aims to reverse fatty liver damage in MASH patients
Disease control Recruiting nowThis study tests a new medicine, IBI362, in 165 adults with MASH, a serious fatty liver disease that can lead to scarring. Participants will receive either a low dose, high dose, or a placebo for 60 weeks. The main goal is to see if the drug can improve liver health without makin…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New weekly shot aims to reverse fatty liver damage
Disease control Recruiting nowThis study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gut bugs linked to liver damage in new study
Knowledge-focused Recruiting nowThis study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
MASH patients share their hopes and challenges in new interview study
Knowledge-focused Recruiting nowThis study interviews 25 people with MASH (a fatty liver disease linked to metabolism) to learn about their expectations, attitudes, and unmet needs before and after joining a special heart-liver program. Participants will have two private interviews. The goal is to improve care …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC